atazanavir sulfate has been researched along with pyrroles in 5 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (pyrroles) | Trials (pyrroles) | Recent Studies (post-2010) (pyrroles) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 26,129 | 2,815 | 12,100 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Araínga, M; Ciborowski, P; Dash, PK; Gelbard, HA; Gendelman, HE; Goodfellow, VS; Gorantla, S; Guo, D; Haverland, NA; Knibbe-Hollinger, J; Liu, XM; Martinez-Skinner, A; McMillan, JM; Poluektova, LY; Wiederin, JL; Wysocki, BJ; Wysocki, TA; Zhang, G | 1 |
| Alnouti, Y; Bade, AN; Dash, PK; Edagwa, B; Gautam, N; Gelbard, HA; Gendelman, HE; Gnanadhas, DP; Gorantla, S; Lin, Z; McMillan, J; Mosley, RL; Palandri, DL; Sillman, B | 1 |
| Dash, PK; Edagwa, B; Gelbard, H; Gendelman, HE; Gnanadhas, DP; Gorantla, S; Lin, Z; Machhi, J; McMillan, J; Thomas, MB | 1 |
1 trial(s) available for atazanavir sulfate and pyrroles
| Article | Year |
|---|---|
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
4 other study(ies) available for atazanavir sulfate and pyrroles
| Article | Year |
|---|---|
Recent changes to FDA-approved labeling.
Topics: Acetamides; Aminoquinolines; Atazanavir Sulfate; Atorvastatin; Botulinum Toxins, Type A; Dosage Forms; Drug Labeling; Epoetin Alfa; Erythropoietin; Heptanoic Acids; Humans; Imiquimod; Insulin; Insulin Lispro; Mandelic Acids; Oligopeptides; Oseltamivir; Pyridines; Pyrroles; Recombinant Proteins; United States; United States Food and Drug Administration | 2004 |
The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Topics: Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; MAP Kinase Kinase Kinases; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinase Kinase 11; Nanocapsules; Protein Kinase Inhibitors; Pyridines; Pyrroles; Treatment Outcome | 2016 |
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Female; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Macrophages; Male; Mice; Nanoparticles; Oxazines; Piperazines; Pyridines; Pyridones; Pyrroles | 2017 |
Modulating cellular autophagy for controlled antiretroviral drug release.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Autophagy; beta-Cyclodextrins; Cell Survival; Clomipramine; Clonidine; Drug Carriers; Drug Interactions; Drug Liberation; HIV-1; Humans; Macrophages; Metformin; Nanoparticles; Particle Size; Pyridines; Pyrroles; Sirolimus; Tissue Distribution | 2018 |